CN105431445A - 使用S-[4-(3-氟-3-甲基丁酰氧基)丁-2-炔基]6α，9α-二氟-17α-(呋喃-2-基)羰氧基-11β-羟基-16α-甲基-3-氧代雄甾-1，4-二烯-17β-硫代羧酸酯治疗炎性疾病的方法 - Google Patents

使用S-[4-(3-氟-3-甲基丁酰氧基)丁-2-炔基]6α，9α-二氟-17α-(呋喃-2-基)羰氧基-11β-羟基-16α-甲基-3-氧代雄甾-1，4-二烯-17β-硫代羧酸酯治疗炎性疾病的方法 Download PDF

Info

Publication number
CN105431445A
CN105431445A CN201480030607.2A CN201480030607A CN105431445A CN 105431445 A CN105431445 A CN 105431445A CN 201480030607 A CN201480030607 A CN 201480030607A CN 105431445 A CN105431445 A CN 105431445A
Authority
CN
China
Prior art keywords
compound
formula
inflammatory
disease
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480030607.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·帕特尔
G·C·帕特尔
G·S·谢思
S·N·曼德汉
C·T·拉奥
R·森纳提
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of CN105431445A publication Critical patent/CN105431445A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN201480030607.2A 2013-05-28 2014-05-28 使用S-[4-(3-氟-3-甲基丁酰氧基)丁-2-炔基]6α，9α-二氟-17α-(呋喃-2-基)羰氧基-11β-羟基-16α-甲基-3-氧代雄甾-1，4-二烯-17β-硫代羧酸酯治疗炎性疾病的方法 Pending CN105431445A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1881/MUM/2013 2013-05-28
IN1881MU2013 2013-05-28
PCT/IN2014/000359 WO2014192027A1 (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Publications (1)

Publication Number Publication Date
CN105431445A true CN105431445A (zh) 2016-03-23

Family

ID=51300796

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480030607.2A Pending CN105431445A (zh) 2013-05-28 2014-05-28 使用S-[4-(3-氟-3-甲基丁酰氧基)丁-2-炔基]6α，9α-二氟-17α-(呋喃-2-基)羰氧基-11β-羟基-16α-甲基-3-氧代雄甾-1，4-二烯-17β-硫代羧酸酯治疗炎性疾病的方法

Country Status (18)

Country Link
US (1) US9458187B2 (enExample)
EP (1) EP3004133B1 (enExample)
JP (1) JP6366696B2 (enExample)
KR (1) KR20160030085A (enExample)
CN (1) CN105431445A (enExample)
AU (1) AU2014272640B2 (enExample)
BR (1) BR112015029530A8 (enExample)
CA (1) CA2912400A1 (enExample)
EA (1) EA027831B9 (enExample)
ES (1) ES2664019T3 (enExample)
IL (1) IL242658A0 (enExample)
MX (1) MX2015016283A (enExample)
MY (1) MY179214A (enExample)
PH (1) PH12015502652A1 (enExample)
SG (1) SG11201509680TA (enExample)
UA (1) UA117248C2 (enExample)
WO (1) WO2014192027A1 (enExample)
ZA (1) ZA201508640B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6366696B2 (ja) 2013-05-28 2018-08-01 スン プハルマ アドバンセド リサーチ カンパニー リミテド Ｓ−［４−（３−フルオロ−３−メチルブチリルオキシ）ブタ−２−イニル］６α，９α−ジフルオロ−１７α−（フラン−２−イル）カルボニルオキシ−１１β−ヒドロキシ−１６α−メチル−３−オキソアンドロスタ−１，４−ジエン−１７β−カルボチオアートを使用する炎症性病態の治療の方法
AU2016210812A1 (en) 2015-01-31 2017-08-17 Sun Pharma Advanced Research Company Limited Crystalline form of S-(4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl)6alpha, 9alpha -difluoro-17alpha,-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha-methy1-3-oxoandrosta-1,4-diene-17beta-carbothioate
CN106279341A (zh) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 一种糠酸氟替卡松的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101384610A (zh) * 2006-01-27 2009-03-11 太阳医药高级研究有限公司 新型11β-羟基雄甾-4-烯-3-酮

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1201114A (en) 1980-02-15 1986-02-25 Gordon H. Phillipps Androstane carbothioates
US7208613B2 (en) 2002-06-20 2007-04-24 Sun Pharmaceutical Industries Limited Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
JP6366696B2 (ja) 2013-05-28 2018-08-01 スン プハルマ アドバンセド リサーチ カンパニー リミテド Ｓ−［４−（３−フルオロ−３−メチルブチリルオキシ）ブタ−２−イニル］６α，９α−ジフルオロ−１７α−（フラン−２−イル）カルボニルオキシ−１１β−ヒドロキシ−１６α−メチル−３−オキソアンドロスタ−１，４−ジエン−１７β−カルボチオアートを使用する炎症性病態の治療の方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101384610A (zh) * 2006-01-27 2009-03-11 太阳医药高级研究有限公司 新型11β-羟基雄甾-4-烯-3-酮

Also Published As

Publication number Publication date
MX2015016283A (es) 2016-03-11
EA027831B1 (ru) 2017-09-29
ZA201508640B (en) 2017-09-27
UA117248C2 (uk) 2018-07-10
MY179214A (en) 2020-11-02
KR20160030085A (ko) 2016-03-16
US20160102117A1 (en) 2016-04-14
EP3004133A1 (en) 2016-04-13
EA027831B9 (ru) 2017-12-29
BR112015029530A8 (pt) 2019-12-17
EP3004133B1 (en) 2018-03-07
SG11201509680TA (en) 2015-12-30
AU2014272640A1 (en) 2015-11-26
ES2664019T3 (es) 2018-04-18
US9458187B2 (en) 2016-10-04
CA2912400A1 (en) 2014-12-04
WO2014192027A1 (en) 2014-12-04
AU2014272640B2 (en) 2018-04-05
EA201592283A1 (ru) 2016-04-29
IL242658A0 (en) 2016-02-01
PH12015502652A1 (en) 2016-03-07
JP2016520122A (ja) 2016-07-11
JP6366696B2 (ja) 2018-08-01
BR112015029530A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
EP1775305B1 (en) 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent
JP5097129B2 (ja) 新規１１β−ヒドロキシアンドロスタ−４−エン−３−オン
US20120142651A1 (en) Method of treatment of allergic rhinitis
US20110182828A1 (en) C20-c21 substituted glucocorticoid receptor agonists
EP1893220A1 (en) Substituted phenylphosphates as mutual prodrugs of steroids and beta -agonists for the treatment of pulmonary inflammation and bronchoconstriction
US20110262368A1 (en) C21 thioethers as glucocorticoid receptor agonists
JPH08508278A (ja) 新規プレドニソロン誘導体
US7629335B2 (en) Anti-inflammatory androstane derivative
CN105431445A (zh) 使用S-[4-(3-氟-3-甲基丁酰氧基)丁-2-炔基]6α，9α-二氟-17α-(呋喃-2-基)羰氧基-11β-羟基-16α-甲基-3-氧代雄甾-1，4-二烯-17β-硫代羧酸酯治疗炎性疾病的方法
US20120171126A1 (en) NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF
US11447522B2 (en) Potent soft anti-inflammatory corticosteroid compounds and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20190924

AD01 Patent right deemed abandoned